Risk factors for melanoma among survivors of non-Hodgkin lymphoma
the ONA take:
Investigators sought to quantify risks associated with specific treatments and immune-related risk factors for cutaneous melanoma among survivors of non-Hodgkin lymphoma.
This research follows previous studies that reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of developing cutaneous melanoma.
Risk of second melanoma was evaluated in 44,870 1-year survivors of first primary NHL. A total of 202 second melanoma cases were identified among the survivors, including 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL subtypes.
This research revealed a significantly increased risk of melanoma among survivors of CLL/SLL who received infused fludarabine-containing chemotherapy with or without rituximab. Risk of melanoma was not associated with specific treatments among survivors of other subtypes of NHL.
The investigators conclude that immune perturbation may contribute to risk of melanoma after CLL/SLL. Survivors of NHL should be vigilantly followed to ensure early detection of melanoma.
Survivors of non-Hodgkin lymphoma have an increased risk of developing cutaneous melanoma.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
- Exercise May Mitigate Cardiotoxicity Associated With Doxorubicin Treatment
- Mobile Health Apps Becoming More Popular Among Patients and Clinicians
- Online Learning Modules Improve Exercise Counseling, But Not Participation
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|